Avalo Therapeutics (AVTX)

• Market cap: $89.9M
• 1 day: -3.59%
• 5 days: -9.58%
• 1 month: -12.61%
• 3 months: -11.17%
• 6 months: -36.04%
• Year to date: -1.38%
• 1 year: -31.17%
• 5 years: -99.94%
• 10 years: -99.93%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 19

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

557% more capital invested

Capital invested by funds: $9.62M [Q2] → $63.2M (+$53.6M) [Q3]

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

38% more funds holding

Funds holding: 21 [Q2] → 29 (+8) [Q3]

6.24% less ownership

Funds ownership: 74.87% [Q2] → 68.63% (-6.24%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $24 179% upside
• Avg. target: $32 273% upside
• High target: $40 366% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

BTIG Julian Harrison 33% 1-year accuracy 6 / 18 met price target	366% upside $40	Buy Initiated	19 Dec 2024
LUCID CAPITAL MARKETS Dev Prasad 33% 1-year accuracy 1 / 3 met price target	179% upside $24	Buy Initiated	17 Dec 2024